Results 261 to 270 of about 406,416 (358)

Prediction of dose reductions and impact of reduced starting doses of CDK4/6i on effectiveness in HR‐positive/HER2‐negative metastatic breast cancer: Real‐world data from the OPAL registry

International Journal of Cancer, EarlyView.
What's New? Balancing efficacy and tolerability is challenging in oncology, as standard dosing often prioritizes maximum tolerated doses over other patient needs. Here, the authors developed a predictive index to identify patients with increased probability of dose reduction in metastatic breast cancer and compared the real‐world effectiveness of ...
Patrick Marschner, Kai Ringwald, Marc Thill, Mark‐Oliver Zahn, Anja Welt, Arnd Nusch, Gabriele Kaltenecker, Yolanda Rodemer, Volker Hagen, Caroline Schock, Lisa Kruggel, Anja Kaiser‐Osterhues, Dunja Klein, Nina Haug, Elmar Stickeler, Nadia Harbeck, Achim Wöckel, Norbert Marschner, Thomas Decker, the OPAL Registry Group   +19 more
wiley   +1 more source

CDK9 interacts with a RanGTP-importin-β complex to regulate erythroid enucleation. [PDF]

J Cell Sci
Newton LM, Lim KYB, Abeid DY, Wölwer CB, Johnson CJ, Russell SM, Hawkins ED, Humbert PO.   +7 more
europepmc   +1 more source

Multidisciplinary Strategies for Targeting Tumor Dormancy in Breast Cancer Therapeutics: Hallmarks, Mechanism, and Approaches

iMetaMed, EarlyView.
Clinical phases and classification of breast tumor dormancy. Tumor dormancy is described as the period after treatment until residual tumor cells become detectable as relapsing disease in clinic. During the period of clinical tumor dormancy, tumor mass dormancy and cellular dormancy may coexist.
Shu Chen, Hui Chen, Vijaya Raghavan, Jing Huang, Jin Wang   +4 more
wiley   +1 more source

Comparison of the enzymatic and cellular profiles of clinical JAK inhibitors for the treatment of myelofibrosis. [PDF]

Blood Neoplasia
Celik H, Wass B, Zolotarjova N, Trivedi G, Margulis A, Drake K, Covington M, Laranjeira ABA, Katiyar K, Smith A, Zhang G, Macarrón R.   +11 more
europepmc   +1 more source

Holistic bone developing microenvironment engineered apoptotic extracellular vesicles recapitulate multidimensional developmental signatures in adult and senile bone repair

Interdisciplinary Medicine, EarlyView.
The developing bone was identified as an M2a‐like macrophage driven immune microenvironment with multidimensional developmental signatures. hME‐ApoEVs were successfully fabricated via stimulating the M2a‐like developing microenvironment in vitro and confirmed its recapitulation of developmental features.
Xiaoran Yu, Jieyun Xu, Yuan Zhao, Xinyu Guo, Hongcheng Chen, Junlong Xue, Yong Ao, Linjun Zhang, Xiaomeng Gao, Xueli Mao, Songtao Shi, Zetao Chen   +11 more
wiley   +1 more source

Astaxanthin suppresses hepatocellular carcinoma via targeting Wnt/Β-catenin pathway: Experimental study on chemically induced HCC in rats. [PDF]

Sci Rep
Kortam MA, Ismail MS, Kamel MA, El-Boghdady NA.   +3 more
europepmc   +1 more source

Engineered extracellular vesicles for precision renal therapy: Bioengineering strategies and clinical translation

Interdisciplinary Medicine, EarlyView.
Engineered extracellular vesicles (EVs) offer a versatile platform for kidney‐targeted therapy. This review summarizes bioengineering strategies, including cargo loading, surface modification, biomimetic fabrication, and biomaterial integration. We highlight translational challenges and propose future solutions to accelerate the clinical application of
Linru Shi, Bei Li, Wanzhu Liu, Haifeng Wu, Wenrong Xu, Cheng Ji, Hui Qian   +6 more
wiley   +1 more source

FGF23 Controls Myocardial Fibrosis Progression via Promoting Cardiac Fibroblast Proliferation and Activation in Mice. [PDF]

Biology (Basel)
Shen L, Hu M, Xue M, Li S.
europepmc   +1 more source

The Role and Regulation of Cyclin G2 in Human Ovarian Cancer Cells

, 2014
Stephanie Bernaudo
openalex   +1 more source

SUMOylation regulates tumorigenesis and progression: Molecular mechanisms and therapeutic applications

Interdisciplinary Medicine, EarlyView.
SUMOylation, a dynamic post‐translational modification, acts as a master regulator at the heart of tumor malignancy. Our work delineates how the SUMOylation cycle—mediated by E1/E2/E3 enzymes and reversed by SENPs—orchestrates multiple hallmarks of cancer. The central pathway converges on three critical pathological axes: 1.
Yimao Wu, Zichang Chen, Yinting Hu, Gokhan Zengin, Qian Zhang, Meng‐Yao Li, Wenlong Sun   +6 more
wiley   +1 more source